Search results
Results from the WOW.Com Content Network
Risk Evaluation and Mitigation Strategies (REMS) is a program of the US Food and Drug Administration for the monitoring of medications with a high potential for serious adverse effects. REMS applies only to specific prescription drugs, but can apply to brand-name or generic drugs. [1] The REMS program was formalized in 2007.
Once a doctor decides a patient is a candidate for isotretinoin, [10] they counsel the patient to ensure they understand the drug and the potential side effects. Once the patient signs the necessary paperwork, their doctor will give them a patient ID number, ID card, and program educational materials.
Login.gov is a single sign-on solution for US government websites. [1] It enables users to log in to services from numerous government agencies using the same username and password. Login.gov was jointly developed by 18F and the US Digital Service . [ 1 ]
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NAS: CELG) , announced today the initiation of the "Innovation Impact" Awards to recognize effective, innovative and successful initiatives in ...
In 2018, Celgene was at the top of a list of companies that the FDA identified as refusing to release samples to competitors to create generics. [53] Generic manufacturer Lannett Company initiated antitrust litigation that accused Celgene of using its REMS for THALOMID (thalidomide) to violate the anti-monopolization provisions of the Sherman ...
In July 2010, HHS published new rules for recognizing testing and certification bodies, which were scheduled to take effect when the new bodies were named. In September 2010, the Office of the National Coordinator (ONC) of HHS named CCHIT again under these new rules. CCHIT is an ONC-Authorized Testing and Certification Body (ONC-ATCB).
You may be prompted to get a verification code at your recovery phone number or recovery email address for any of the following reasons:
In June, the company announced a 10-year partnership with Celgene valued at $1 billion. [9] As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno's therapies around the world.